Citadel Advisors’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $214M | Buy |
360,643
+173,479
| +93% | +$86.4M | 0.03% | 433 |
|
|
2025
Q4 | $91.2M | Sell |
187,164
-86,818
| -32% | -$40.4M | 0.01% | 928 |
|
|
2025
Q3 | $115M | Buy |
273,982
+132,971
| +94% | +$44.7M | 0.02% | 743 |
|
|
2025
Q2 | $40.5M | Buy |
141,011
+104,827
| +290% | +$31.3M | 0.01% | 1406 |
|
|
2025
Q1 | $11.2M | Buy |
36,184
+15,846
| +78% | +$5.43M | ﹤0.01% | 2706 |
|
|
2024
Q4 | $7.18M | Buy |
+20,338
| New | +$7.48M | ﹤0.01% | 3406 |
|
|
2024
Q2 | – | Sell |
-719,311
| Closed | -$190M | – | 15475 |
|
|
2024
Q1 | $165M | Buy |
719,311
+641,414
| +823% | +$145M | 0.03% | 445 |
|
|
2023
Q4 | $17.1M | Buy |
77,897
+56,825
| +270% | +$13.1M | ﹤0.01% | 2169 |
|
|
2023
Q3 | $4.76M | Sell |
21,072
-22,252
| -51% | -$5.13M | ﹤0.01% | 3726 |
|
|
2023
Q2 | $9.56M | Sell |
43,324
-10,776
| -20% | -$2.39M | ﹤0.01% | 2735 |
|
|
2023
Q1 | $12.1M | Sell |
54,100
-270,831
| -83% | -$66.8M | ﹤0.01% | 2553 |
|
|
2022
Q4 | $90.4M | Sell |
324,931
-289,581
| -47% | -$73.1M | 0.02% | 701 |
|
|
2022
Q3 | $129M | Buy |
614,512
+555,159
| +935% | +$124M | 0.03% | 484 |
|
|
2022
Q2 | $14M | Sell |
59,353
-174,171
| -75% | -$35.4M | ﹤0.01% | 2261 |
|
|
2022
Q1 | $41.9M | Buy |
233,524
+114,607
| +96% | +$21.8M | 0.01% | 1246 |
|
|
2021
Q4 | $25.7M | Sell |
118,917
-202,582
| -63% | -$39.8M | 0.01% | 1748 |
|
|
2021
Q3 | $59.3M | Buy |
321,499
+82,426
| +34% | +$16.2M | 0.01% | 995 |
|
|
2021
Q2 | $42.9M | Sell |
239,073
-80,538
| -25% | -$15.3M | 0.01% | 1262 |
|
|
2021
Q1 | $53.5M | Sell |
319,611
-412,397
| -56% | -$68.8M | 0.01% | 999 |
|
|
2020
Q4 | $111M | Buy |
732,008
+103,306
| +16% | +$13.6M | 0.03% | 494 |
|
|
2020
Q3 | $63.5M | Sell |
628,702
-250,889
| -29% | -$27.5M | 0.02% | 702 |
|
|
2020
Q2 | $106M | Sell |
879,591
-525,343
| -37% | -$59.1M | 0.04% | 376 |
|
|
2020
Q1 | $133M | Buy |
1,404,934
+173,427
| +14% | +$16.5M | 0.06% | 238 |
|
|
2019
Q4 | $108M | Sell |
1,231,507
-228,098
| -16% | -$20.1M | 0.05% | 356 |
|
|
2019
Q3 | $116M | Buy |
1,459,605
+771,704
| +112% | +$62.1M | 0.05% | 340 |
|
|
2019
Q2 | $53.7M | Buy |
687,901
+683,034
| +14,034% | +$63.9M | 0.02% | 683 |
|
|
2019
Q1 | $571K | Sell |
4,867
-21,669
| -82% | -$2.52M | ﹤0.01% | 6579 |
|
|
2018
Q4 | $2.89M | Sell |
26,536
-74,392
| -74% | -$8.63M | ﹤0.01% | 3584 |
|
|
2018
Q3 | $12.9M | Buy |
100,928
+10,481
| +12% | +$1.3M | 0.01% | 1820 |
|
|
2018
Q2 | $10.2M | Sell |
90,447
-60,851
| -40% | -$6.69M | 0.01% | 1900 |
|
|
2018
Q1 | $17M | Buy |
151,298
+130,068
| +613% | +$16.5M | 0.01% | 1264 |
|
|
2017
Q4 | $3.14M | Sell |
21,230
-56,198
| -73% | -$7.14M | ﹤0.01% | 3040 |
|
|
2017
Q3 | $9.07M | Buy |
77,428
+48,948
| +172% | +$6.25M | 0.01% | 1691 |
|
|
2017
Q2 | $3.69M | Sell |
28,480
-8,443
| -23% | -$1.05M | ﹤0.01% | 2451 |
|
|
2017
Q1 | $5M | Sell |
36,923
-2,809
| -7% | -$426K | ﹤0.01% | 2045 |
|
|
2016
Q4 | $5.7M | Sell |
39,732
-53,071
| -57% | -$6.78M | 0.01% | 1858 |
|
|
2016
Q3 | $11M | Buy |
92,803
+78,668
| +557% | +$9.45M | 0.01% | 1280 |
|
|
2016
Q2 | $1.5M | Sell |
14,135
-231,390
| -94% | -$25.8M | ﹤0.01% | 3058 |
|
|
2016
Q1 | $27.4M | Buy |
245,525
+233,485
| +1,939% | +$29.5M | 0.03% | 576 |
|
|
2015
Q4 | $1.89M | Sell |
12,040
-75,316
| -86% | -$11M | ﹤0.01% | 2812 |
|
|
2015
Q3 | $11.5M | Buy |
87,356
+61,521
| +238% | +$9.87M | 0.01% | 1249 |
|
|
2015
Q2 | $4.49M | Buy |
25,835
+24,789
| +2,370% | +$4.46M | ﹤0.01% | 2170 |
|
|
2015
Q1 | $180K | Sell |
1,046
-668,097
| -100% | -$102M | ﹤0.01% | 6305 |
|
|
2014
Q4 | $86.6M | Buy |
669,143
+117,749
| +21% | +$15.2M | 0.09% | 244 |
|
|
2014
Q3 | $70.9M | Buy |
551,394
+491,540
| +821% | +$50.7M | 0.07% | 283 |
|
|
2014
Q2 | $5.3M | Buy |
59,854
+54,427
| +1,003% | +$5.23M | 0.01% | 1784 |
|
|
2014
Q1 | $510K | Sell |
5,427
-13,786
| -72% | -$1.41M | ﹤0.01% | 4321 |
|
|
2013
Q4 | $2.17M | Sell |
19,213
-7,733
| -29% | -$697K | ﹤0.01% | 2473 |
|
|
2013
Q3 | $2.13M | Buy |
26,946
+18,377
| +214% | +$1.34M | ﹤0.01% | 2359 |
|
|
2013
Q2 | $564K | Buy |
+8,569
| New | +$552K | ﹤0.01% | 3714 |
|
Other funds holding UTHR
ACA
VPM
VCM
Citadel Advisors's UTHR Position: Q1 2026 in Review
Citadel Advisors increased its United Therapeutics (UTHR) stake by 93% in Q1 2026, buying an estimated $86.4M and bringing the position to 360,643 shares worth $214M. The position accounts for 0.03% of the portfolio, ranked #433.
Citadel Advisors first reported a position in UTHR in Q2 2013 and has held it in 50 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- Citadel Advisors held 360,643 shares of United Therapeutics worth $214M as of Q1 2026.
- Citadel Advisors bought 173,479 United Therapeutics shares in Q1 2026, an estimated $86.4M.
- United Therapeutics made up 0.03% of Citadel Advisors's portfolio in Q1 2026, its #433 holding.
- Citadel Advisors first reported a position in United Therapeutics in Q2 2013 and has held it in 50 quarters since.
- 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.